Mismatch Negativity

Mismatch Negativity (MMN) is a unique neural feature that emerges when an individual detects any unexpected or deviant auditory stimulus. It is an important component of the auditory event-related potential that is used to study cognitive and sensory processing in the brain. MMN is generated in the brain’s auditory cortex and is associated with both sensory and memory-based cognitive processing. Several neurological and clinical studies suggest that MMN could be used as a potential biomarker for several health conditions, including neurological disorders such as Alzheimer's, Schizophrenia, and Autism. It could also be helpful in identifying hearing deficiencies in infants, detecting early-onset hearing impairment in adults, and providing insight into language learning disabilities. As an important therapeutic tool, MMN is being used in Neurofeedback therapy for the rehabilitation of individuals with neurological disorders. This has been found to be quite effective in improving cognitive processes in individuals with brain damage or those recovering from a stroke. MMN-based therapies can also be useful for improving language recognition, increasing social interaction, and reducing negative behavior in children with developmental disorders. In recent years, MMN has emerged as an essential diagnostic and therapeutic tool in the field of neurological research and therapy. The ability to utilize MMN for the diagnosis and treatment of various neurological disorders could revolutionize the way we approach the treatment of brain conditions. Furthermore, with the advancement of medical technology, we can only expect to get more profound insights into MMN-based therapies and how they can be utilized to help those who need it the most.


From: Journal of Neurological Research And Therapy

Related Article For "Mismatch Negativity"

About (2) results

Article:

The Effect of HLA-DRB1 Allele Mismatch on the Results after Hematopoietic Stem Cell Transplantation

Journal:

Bone Marrow Biology

Article:

Successful Allogeneic Hematopoietic Stem Cell Transplantation from A 5/10 Mismatched Unrelated Donor in A Patient with Donor-Specific Anti-HLA Antibodies.

Journal:

Hematology and Oncology Research